2025 Analysis: Opportunities and Risks in the Evolving Diffuse Large B-cell Lymphoma Therapeutics Market
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Outlook for the Diffuse Large B-cell Lymphoma Therapeutics Market Heading Into 2029?
The market for therapeutics for diffuse large b-cell lymphoma has seen substantial growth in recent periods. The market size is projected to increase from $4.74 billion in 2024 to $5.1 billion in 2025, representing a compound annual growth rate (CAGR) of 7.5%. The growth experienced in the historic period is a result of advancements in clinical research, approval by regulatory bodies, improved patient awareness and diagnosis, collaborative efforts, and ongoing development of care standards.
In the coming years, the market for therapeutics for diffuse large b-cell lymphoma is projected to witness robust growth, expanding to “$6.92 billion by 2029 with a compound annual growth rate (CAGR) of 7.9%. Factors contributing to this prediction include advancements in immunotherapy and biomarker discovery, growing frequencies of the disease, an ageing global population, and enhancements in healthcare infrastructure including greater access to innovative drugs. The forecasted era is likely to see trends like the emergence of outpatient treatment facilities, joined clinical trials, patient-focused care models, advancements in diagnostic imaging techniques, and the digitalization of healthcare.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10805&type=smp
Which Factors Are Pushing The Diffuse Large B-cell Lymphoma Therapeutics Market Forward?
A rise in the occurrences of diffuse large B-cell lymphoma (DLBCL), a type of aggressive cancer that stems from B-cells in the lymph system and typified by swift and diffuse expansion, is anticipated to stimulate the expansion of the market for DLBCL therapeutics. These treatments work to enhance results for those already diagnosed with DLBCL by combating and controlling the proliferation of cancer cells. The American Cancer Society, a reputed voluntary health entity in the US, has projected that by 2023, around 80,550 individuals (comprising 44,880 males and 35,670 females) will be diagnosed with non-Hodgkin lymphoma (NHL), out of which about 20,180 are expected to succumb to it. As a result, the escalating incidence of DLBCL is propelling the growth of its therapeutics market.
The diffuse large b-cell lymphoma therapeutics market covered in this report is segmented –
1) By Drug Class: Cisplatin, Carboplatin, 5-fluorouracil, Docetaxel, Paclitaxel, Methotrexate, Other Drugs
2) By Therapy: Targeted Therapy, Immunotherapy, Chemotherapy, Other Therapies
3) By Route of Administration: Oral, Parenteral, Other Routes
4) By End User: Hospitals, Clinics, Other End-Users
Subsegments:
1) By Cisplatin: Injection Formulations, Combination Therapies
2) By Carboplatin: Injection Formulations, Combination Therapies
3) By 5-Fluorouracil: Injection Formulations, Oral Formulations
4) By Docetaxel: Injection Formulations, Combination Therapies
5) By Paclitaxel: Injection Formulations, Combination Therapies
6) By Methotrexate: Injection Formulations, Oral Formulations, Combination Therapies
7) By Other Drugs: Monoclonal Antibodies, Targeted Therapies, Immunotherapies, Experimental Therapies
What Long-Term Trends Are Likely To Affect The Diffuse Large B-cell Lymphoma Therapeutics Market?
In the diffuse large B-cell lymphoma therapeutics market, there is an increasing trend for the development of therapeutic drugs. Key players in the market are working on creating these new therapies in order to maintain their market standing. For instance, Bristol-Myers Squibb, an American pharmaceutical company specializing in drug research and development, obtained US FDA approval for its CAR T Cell Therapy Breyanzi in June 2022. This therapy was developed for treating patients with diffuse large B-cell lymphoma (DLBCL), large B-cell lymphoma (LBCL), and relapsed or refractory large B-cell lymphoma. Breyanzi, a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, is available for an array of patients with primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and follicular lymphoma grade 3B.
Which Organizations Are Driving Progress In The Diffuse Large B-cell Lymphoma Therapeutics Industry?
Major companies operating in the diffuse large B-cell lymphoma therapeutics market include Novartis AG, Pfizer Inc., Merck & Co Inc., GlaxoSmithKline plc, F. Hoffmann-La Roche AG, CTI BioPharma Corp., Celltrion Healthcare Co Ltd., Bristol-Myers Squibb Company, AbbVie Inc., Gilead Sciences Inc., Seagen Inc., Kite Pharma Inc., ADC Therapeutics SA, Bayer AG, Xencor Inc., Autolus Therapeutics plc, Allogene Therapeutics Inc., Spectrum Pharmaceuticals Inc., AstraZeneca PLC, Aptevo Therapeutics Inc., Takeda Pharmaceutical Company Limited, Johnson & Johnson, Celgene Corporation, Eli Lilly and Company, Sanofi SA, Seattle Genetics Inc., Karyopharm Therapeutics Inc., TG Therapeutics Inc., MorphoSys AG
Which Region Is Expected To Experience The Highest Growth In The Diffuse Large B-cell Lymphoma Therapeutics Industry?
North America was the largest region in the global diffuse large B-cell lymphoma therapeutics market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diffuse large B-cell lymphoma therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=10805&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
